Report Summary
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.
- Comprehensive directory of diagnostic deals since 2007
- Diagnostic contract documents
- Diagnostic agreement terms
- Diagnostic agreement structure
- Top diagnostic deals by value
- Most active diagnostic dealmakers
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all diagnostics partnering deals announced since January
2007, including financial terms where available, including over 3,000 links to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Diagnostics Partnering Terms and Agreements Report
Published: February 2012
No.OF Pages: 1332
Price: Single User License US$ 2695
Table of Contents
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in diagnostic dealmaking
2.1. Introduction
2.2. Diagnostic partnering over the years
2.3. Most active diagnostic dealmakers
2.4. Bigpharma diagnostic dealmaking activity
2.5. Bigpharma not active in diagnostics
2.6. Diagnostics partnering by deal type
2.7. Diagnostics partnering by stage of development
2.8. Diagnostics partnering by disease type
2.9. Average deal terms for diagnostics partnering
2.9.1 Diagnostics partnering headline values
2.9.2 Diagnostic deal upfront payments
2.9.3 Diagnostics royalty rates
2.10. The anatomy of diagnostic partnering
2.10.1. The anatomy of a diagnostic deal
2.10.1.a. Case study 1: Sequenom – Lenetex – January 2007
2.10.1.b. Case study 2: Celera – Siemens Medical Solutions – July 2007
2.10.1.c. Case study 3: US Genomics – Rosetta Genomics – May 2006
2.11. Litigation and settlement in diagnostics
Chapter 3 – Leading diagnostic deals
3.1. Introduction
3.2. Top diagnostic deals by value
3.3. Top diagnostic deals involving bigpharma
3.4. Leading diagnostics M&A deals by value
Chapter 4 – Bigpharma diagnostic deals
4.1. Introduction
4.2. How to use bigpharma diagnostic partnering deals
4.3. Bigpharma partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
Chapter 5 – Diagnostic dealmaking directory
5.1. Introduction
5.2. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Interests
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing – OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
5.4. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hormonal
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organs
Chapter 6 – Diagnostic partnering resource center
6.1. Online diagnostic partnering
6.2. Diagnostic partnering events
6.3. Further reading on diagnostic dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example diagnostics partnering agreement
About CurrentPartnering
Recent titles from CurrentPartnering
Order Form – Reports
List of Figures